School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Ultragenyx Pharmaceutical Inc RARE

Healthcare · Biotechnology

$15.48last close 2026-10-09 · market cap $1.53B · delayed data

Trailing returns

1M+8.18%
3M-55.27%
6M-35.26%
1Y-51.11%
5Y-81.04%

Basis: Adjusted daily closes.

What it does

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Open RARE in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies